While amyloid beta has dominated Alzheimer's research for decades, a lesser-known protein called tau may be equally responsible for brain damage in Alzheimer's and more than two dozen other neurodegenerative diseases. New research from the University of Colorado Boulder reveals how tau tangles form and spread, and proposes a novel strategy that halted or reversed neurodegeneration in mice. What Is Tau and Why Does It Matter? Tau was first discovered 50 years ago as a protein that helps brain cells maintain their shape and transport important molecules within them. When functioning normally, tau is essential for brain health. However, when tau malfunctions, it transforms into a toxic threat, forming hairball-like tangles inside neurons and spreading through the brain like a virus, killing cells as it goes. This destructive process underlies a group of diseases called "tauopathies." These conditions affect millions of people worldwide and include Alzheimer's disease, which impacts 7 million people in the United States alone. Beyond Alzheimer's, tau-related diseases include chronic traumatic encephalopathy (CTE), commonly found in football players who have experienced repeated head trauma, and frontotemporal dementia, a rapidly progressive disease that causes personality changes and memory loss in adults as young as 40. One particularly concerning tauopathy is subacute sclerosing panencephalitis (SSPE), a fatal condition that develops in about one in 1,000 children who contract measles, typically six to ten years after infection. Why Current Alzheimer's Treatments May Be Missing the Real Problem? The challenge with treating Alzheimer's is timing. In the disease's progression, amyloid beta forms plaques that trigger the spread of tau tangles. However, by the time patients receive treatment, even if doctors can completely eliminate amyloid plaques from the brain, tau has often already caused irreversible damage and continues spreading to healthy neurons. "By the time you treat an Alzheimer's patient, even if you can completely get rid of amyloid plaque in the brain, it's often too late because tau has already done its damage and is continuing to spread," said Roy Parker, distinguished professor of biochemistry and director of the BioFrontiers Institute at CU Boulder. Roy Parker, Distinguished Professor of Biochemistry and Director of the BioFrontiers Institute, University of Colorado Boulder To date, there are no FDA-approved drugs specifically targeting tau, making this research particularly significant. Parker's laboratory and others are working to change that by understanding the molecular mechanisms that cause tau to turn toxic. How Do Tau Proteins Actually Turn Toxic? The breakthrough came from examining postmortem brain tissue of Alzheimer's patients. Researchers noticed that tau aggregates contained unusual proteins with disordered chains of an amino acid called serine. This observation led Parker's team to investigate whether these "polyserines" might be the trigger that causes tau to misfold and become dangerous. Through a series of experiments in human neurons, fruit flies, animals, and human tissue, the researchers confirmed their hypothesis. When polyserine reaches a developing tau seed inside a brain cell, it prompts tau to misfold, clump together, and spread toxic aggregates to neighboring neurons. The team also found that mice with a genetic predisposition to tauopathies who had higher levels of polyserine became sick faster than those with lower levels. "In experiments in human neurons in the test tube, fruit flies, animals and human tissue, we have now shown that overexpression of polyserine increases tau aggregation," explained Parker. Roy Parker, Distinguished Professor of Biochemistry and Director of the BioFrontiers Institute, University of Colorado Boulder Steps to Understanding the New Treatment Strategy - Identifying the Trojan Horse: Researchers transformed polyserine, which naturally gravitates toward tau aggregates, into a delivery vehicle for a protein engineered to break apart tau tangles. - Testing the Approach: Scientists administered the polyserine-attached protein to mice prone to tau aggregation and observed striking decreases in tau aggregates throughout the brain. - Measuring the Results: The treatment reduced the production of new toxic tau seeds, decreased anxiety in the animals, and improved memory deficits compared to untreated mice. The results were remarkable. In mice predisposed to tau aggregation, this strategy either prevented disease from developing altogether or significantly slowed its progression. Could This Lead to a Preventative "Neuronal Vaccine"? The long-term vision for this research extends beyond treating existing disease. Parker and his team hope their findings will eventually inform the development of a preventative treatment that could be given to people at high risk for tauopathies long before symptoms appear. This approach represents a fundamental shift in how neurodegeneration might be addressed. "The holy grail here would be a safe, cheap therapy that is well-tolerated and can be given to people who need it before they have a lot of symptoms," stated Parker. Roy Parker, Distinguished Professor of Biochemistry and Director of the BioFrontiers Institute, University of Colorado Boulder Future research will focus on understanding why polyserine forms in the first place and what other cellular changes contribute to tau's transformation from a beneficial protein into a lethal threat. By understanding how the cellular environment influences this process and how to interfere with it, researchers believe they can move closer to developing effective preventative treatments for Alzheimer's and other tauopathies. The findings were published in two peer-reviewed journals: the Proceedings of the National Academy of Sciences (PNAS) and Neuron, providing strong scientific validation for this novel approach to understanding and potentially treating some of the most devastating neurodegenerative diseases.
